CSPC and its subsidiary, Megalith Biopharma, have submitted the Investigational New Drug (IND) application for SYS6023, an anti-HER3 ADC, in China. SYS6023 In 2021, Megalith Biopharma filed a patent (WO2023088382) covering anti-HER2, anti-HER3, and anti-EGFR ADC, as well as the use thereof. Megalith made a notable change to the payload, opting for JSSW-001, which differs from Daiichi Sankyo's Patritumab deruxtecan (HER3-DXd). In experiments involving the Difi and SW620 colorectal cancer models, the Tumor Growth Inhibition (TGI) of Patritumab-JSSW-001 (DAR=7.36) exceeded that of the HER3 DXd. Anti-HER3 ADC in China SHR-A2009 Hengrui's anti-HER3 ADC, SHR-A2009, is currently in phase 1/2 trials, both as a monotherapy and in combination with Adebrelimab (anti-PD-L1 mAb) or Almonertinib (EGFRi) for non-small cell lung cancer (NSCLC). The first IND application for SHR-A2009 was submitted in August 2021. In October 2023, Hengrui reported the results of phase 1 trial: In evaluable NS
China Biotech XYZ Shares Updates Related to New Drug Development in China